Formulation Development
NGM Bio Discloses Fourth Oncology Development Candidate, NGM831, an ILT3 Antagonist Antibody
NGM Biopharmaceuticals, Inc. recently disclosed its fourth oncology development candidate, NGM831, an antagonist antibody designed to block the interaction of ILT3 with fibronectin, as well…
Zealand Pharma Announces First Patient Dosed in EASE-SBS 4 Phase 3b Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome
Zealand Pharma A/S recently announced dose administration for the first subject in the Phase 3b trial, EASE-SBS 4, evaluating glepaglutide, the company’s long-acting GLP-2 analog,…
Assembly Bio Selects Fourth HBV Core Inhibitor Candidate for Advancement Into Clinical Development
Assembly Biosciences, Inc. recently announced it has selected a fourth core inhibitor candidate, ABI-4334 (4334), that has been optimized for potency, to advance into clinical…
Adial Pharmaceuticals Reaches Full Enrollment Target for ONWARD Phase 3 Trial of AD04 for the Treatment of Patients With Alcohol Use Disorder
Adial Pharmaceuticals, Inc. recently announced it has reached its full enrollment target of 290 subjects in the company’s ONWARD Phase 3 trial evaluating AD04 as…
Curia to Expand US Commercial Manufacturing Capability, Investing More Than $35 Million
Curia, formerly AMRI, a leading contract research, development and manufacturing organization, recently announced plans to expand its commercial manufacturing capacity at its….
IN8bio Completes Dosing of First Cohort in Phase 1 Clinical Trial
IN8bio, Inc. recently announced completion of dosing of the first patient cohort in a Phase 1 clinical trial of INB-100, a donor-derived gamma-delta T cell…
ProPhase Labs Acquires Whole Genome Sequencing Company
ProPhase Labs, Inc. recently announced the acquisition of Nebula Genomics, a privately-owned personal genomics company. The company’s recently formed subsidiary, ProPhase Precision Medicine, Inc., completed…
Crinetics Pharmaceuticals’ Oral ACTH Antagonist Demonstrates Pharmacologic Proof-of-Concept With Dose-Dependent Cortisol Suppression in Single Ascending Dose Portion of Phase 1 Study
Crinetics Pharmaceuticals, Inc. recently announced positive preliminary findings from the single ascending dose (SAD) portion of a first-in-human Phase 1 clinical study with CRN04894 demonstrating pharmacologic…
Valneva Initiates Further Phase 3 Clinical Trial for its COVID-19 Vaccine Candidate
Valneva SE recently announced the initiation of a further Phase 3 trial (VLA2001-304) for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. VLA2001-304 aims to generate…
atai Launches Revixia Life Sciences to Develop Salvinorin A for a Variety of Mental Health Conditions
atai Life Sciences recently announced the launch of Revixia Life Sciences, a wholly owned subsidiary developing Salvinorin A (SalA) to treat a variety of mental…
Terumo Blood & Cell Technologies & PhotonPharma Inc. Announce Collaboration to Develop Novel Cancer Immunotherapy
Terumo Blood and Cell Technologies and PhotonPharma Inc. recently announced they have established a memorandum of understanding (MOU) for collaboration to develop Innocell, a novel….
Lykan Bioscience & Vineti Announce Partnership to Advance Cell-Based Therapies From Clinical to Commercialization
Lykan Bioscience and Vineti recently announced a partnership to unite Lykan’s purpose-built cell therapy manufacturing capabilities and Vineti’s industry-leading….
Dyadic & Sorrento Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate & C1 Technology for Protein-Based Coronavirus Vaccines & Therapeutics
Dyadic International, Inc. and Sorrento Therapeutics, Inc. recently announced the signing of a binding term sheet to enter into a License Agreement to develop and commercialize vaccines, therapeutics, and diagnostics for….
DFE Pharma Demonstrates Impact of Powder Properties on the Rheological Behavior of Excipients
DFE Pharma, a global leader in pharmaceutical excipient solutions, is continuously supporting relevant scientific research and innovations in its field. With the recent publication of…
TriRx Hosted State & Community Leaders to Celebrate Acquisition of Shawnee, KS, Facility
TriRx Pharmaceutical Services, LLC, a leading international CDMO, hosted Kansas Lt. Governor David Toland, Shawnee Mayor Michelle Distler, State Senator Mike Thompson, Congresswoman Jo Ella…
Dotmatics to Deliver the Foundation for Croda’s R&D Digital Program: Artificial Intelligence & Data Mining
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, recently announced it has been selected….
VERAXA Biotech & Indivumed Cooperate on the Development of Precision Oncology Antibody
VERAXA Biotech GmbH, Heidelberg, and Indivumed GmbH, Hamburg, recently announced their agreement to jointly discover modulatory and functional antibodies against several targets that are relevant for….
Daré Bioscience Announces FDA Acceptance & Priority Review of NDA for DARE-BV1 for the Treatment of Bacterial Vaginosis
Daré Bioscience, Inc. recently announced the US FDA accepted for filing the company’s New Drug Application (NDA) for DARE-BV1 for the treatment of bacterial vaginosis…..
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….
ARCA biopharma Announces Submission of PCT Patent Application for the Treatment of COVID-19 Infection & Associated Coagulopathy With rNAPc2
ARCA biopharma, Inc. recently announced it has submitted a Patent Cooperation Treaty (PCT) patent application, following on previously submitted provisional patent applications, for the use…
